<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336580</url>
  </required_header>
  <id_info>
    <org_study_id>PRX004-101</org_study_id>
    <secondary_id>2017-003521-15</secondary_id>
    <nct_id>NCT03336580</nct_id>
  </id_info>
  <brief_title>A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis</brief_title>
  <official_title>A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prothena Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prothena Biosciences Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-label study of intravenous (IV) PRX004 as a single agent in subjects with&#xD;
      hereditary amyloid transthyretin (hATTR) amyloidosis. The study will consist of 3 phases and&#xD;
      will enroll up to a total of 36 subjects. A 3+3 dose escalation component to determine the&#xD;
      safety, tolerability, PK, PD, and MTD. An expansion component in anticipated PRX004 RP2D&#xD;
      cohorts selected from the Dose Escalation Phase. An extended dosing component for eligible&#xD;
      subjects from the Dose Escalation or Expansion phases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1, open-label consists of 3 phases. The Dose Escalation Phase is a 3+3 dose&#xD;
      escalation component to determine the safety, tolerability, PK, PD, and MTD of IV PRX004 when&#xD;
      given as a single agent in up to 36 evaluable subjects with hATTR amyloidosis. The Expansion&#xD;
      Phase is an expansion component in anticipated PRX004 RP2D cohorts selected from the Dose&#xD;
      Escalation Phase (this may occur in addition to cohorts in which additional subjects were&#xD;
      added due to the observation of a dose-limiting [DLT] in the Escalation Phase). The Long-term&#xD;
      Extension (LTE) Phase is an extended dosing component for eligible subjects from the Dose&#xD;
      Escalation or Expansion phases.&#xD;
&#xD;
      The Dose Escalation Phase will follow a standard 3+3 design, in which cohorts of 3 to 6&#xD;
      subjects with hATTR amyloidosis will be enrolled at each dose level to receive IV PRX004 once&#xD;
      every 28 days, based on scheduling from Month 1-Day 1 for up to 3 doses. Each subject will&#xD;
      participate in only 1 dose escalation cohort. The starting dose of PRX004 will be 0.1 mg/kg.&#xD;
&#xD;
      Dose escalation will occur after the third evaluable subject in a cohort has completed the&#xD;
      first 28 days following the first administration of PRX004. Up to 6 dose levels of PRX004 may&#xD;
      be investigated (0.1, 0.3, 1, 3, 10, and 30 mg/kg) if tolerable. In the event the starting&#xD;
      dose of 0.1 mg/kg is not tolerated, the dose escalationwill be halted and the study stopped.&#xD;
&#xD;
      Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase.&#xD;
      Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may&#xD;
      be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.&#xD;
&#xD;
      Each subject will receive a maximum of 3 infusions of PRX004 in the Dose Escalation Phase.&#xD;
      Subjects who complete the Month 3-Day 22 Visit in the Dose Escalation or Expansion phases may&#xD;
      be eligible to receive up to 15 additional PRX004 infusions in the LTE Phase.&#xD;
&#xD;
      Subjects who completed the EOS Visit in the Dose Escalation Phase prior to implementation of&#xD;
      Protocol Amendment 2 may re-enter the study in the LTE Phase if they meet specific&#xD;
      inclusion/exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because of the impact of COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Actual">July 23, 2020</completion_date>
  <primary_completion_date type="Actual">July 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose Escalation Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of PRX004</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum Tolerated Dose of PRX004</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects with treatment-emergent adverse events and clinically significant changes in ECGs, echocardiograms, cardiac telemetry, vital signs, and laboratory evaluations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRX004 pharmacokinetic parameters - Cmin</measure>
    <time_frame>3 months</time_frame>
    <description>Minimum observed concentration (Cmin) of PRX004 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRX004 pharmacokinetic parameters -Cmax</measure>
    <time_frame>3 months</time_frame>
    <description>Maximum observed concentration (Cmax) of PRX004 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRX004 pharmacokinetic parameters - T1/2</measure>
    <time_frame>3 months</time_frame>
    <description>Terminal elimination half-life (T1/2) of PRX004 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRX004 pharmacokinetic parameters -AUClast</measure>
    <time_frame>3 months</time_frame>
    <description>Area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast) of PRX004 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRX004 pharmacokinetic parameters -AUCtau</measure>
    <time_frame>3 months</time_frame>
    <description>Area under the concentration-time curve over the dosing interval (AUCtau) of PRX004 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indicators</measure>
    <time_frame>3 months</time_frame>
    <description>Immunogenicity indicators: Anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Amyloidogenic Transthyretin (ATTR) Amyloidosis</condition>
  <arm_group>
    <arm_group_label>PRX004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation in up to 6 dose levels&#xD;
Expansion of previously studied cohort(s) from Dose Escalation&#xD;
Extended dosing at RP2D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX004</intervention_name>
    <description>PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days&#xD;
PRX004 IV every 28 days at RP2D(s)&#xD;
PRX004 IV every 28 days at RP2D(s)</description>
    <arm_group_label>PRX004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Ability to understand and willingness to sign an informed consent form prior to&#xD;
             initiation of any study procedures&#xD;
&#xD;
          3. Diagnosis of amyloidosis determined by polarizing light microscopy of green&#xD;
             birefringent material in Congo Red-stained tissue specimens; and confirmed diagnosis&#xD;
             of ATTR amyloidosis by immunohistochemistry, mass spectrometry, documentation of an&#xD;
             ATTR mutation by gene sequencing, or 99m&#xD;
             technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scans and/or&#xD;
             technetium pyrophosphate (PYP) SPECT cardiac imaging. If scintigraphy is used for&#xD;
             diagnosis then the grade must be 2 or greater, indicative of transthyretin&#xD;
             amyloidosis-cardiomyopathy (ATTR-CM) (Gillmore, 2016)&#xD;
&#xD;
          4. Known TTR mutation&#xD;
&#xD;
          5. [Inclusion Criterion 5 removed in Amendment 2]&#xD;
&#xD;
          6. Patients receiving concomitant tafamidis or diflunisal may enroll in the study,&#xD;
             providing the dose has been stable for the last 6 months&#xD;
&#xD;
          7. Karnofsky Performance Status (KPS) ≥60%&#xD;
&#xD;
          8. Adequate organ function, including all of the following:&#xD;
&#xD;
               1. Adequate bone marrow reserve, defined as the following: absolute neutrophil count&#xD;
                  ≥1.0 × 109/L; platelet count ≥100 × 109/L; hemoglobin ≥10 g/dL&#xD;
&#xD;
               2. Hepatic: total bilirubin ≤ 2 times the upper limit of normal (× ULN),&#xD;
                  transaminases (aspartate aminotransferase and/or alanine aminotransferase) ≤3 ×&#xD;
                  ULN; alkaline phosphatase ≤5 × ULN&#xD;
&#xD;
               3. Renal: estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2&#xD;
&#xD;
          9. If currently receiving a diuretic, must have been on a stable dose for at least 4&#xD;
             weeks prior to the first dose of study drug&#xD;
&#xD;
         10. Systolic blood pressure ≥90 mmHg and ≤180 mmHg&#xD;
&#xD;
         11. Subjects with cardiomyopathy must have an NT-proBNP ≥650 pg/mL and ≤5000 pg/mL (ie,&#xD;
             ≥76.9 pmol/L and ≤591 pmol/L) or evidence of septal wall thickening &gt;1.2 cm on&#xD;
             echocardiogram&#xD;
&#xD;
         12. Must have a biopsy unless data are available from a previous one. The biopsy may be&#xD;
             taken from any tissue or organ affected by ATTR amyloidosis (eg, skin, lip, abdominal&#xD;
             fat pad, salivary gland), at the Investigator's discretion. Nerve biopsies are not&#xD;
             required.&#xD;
&#xD;
         13. Women of childbearing potential must have 2 negative pregnancy tests during Screening,&#xD;
             the second within 24 hours prior to the first administration of study drug, and must&#xD;
             agree to use highly effective physician-approved contraception from Screening to 90&#xD;
             days following the last study drug administration&#xD;
&#xD;
         14. Male subjects must be surgically sterile or must agree to use highly effective&#xD;
             physician-approved contraception from Screening to 90 days following the last study&#xD;
             drug administration&#xD;
&#xD;
         15. Polyneuropathy Disability (PND) Score ≤IIIB&#xD;
&#xD;
         16. Neuropathy Impairment Score (NIS) ≥5 and ≤130&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Amyloid light chain or other non-ATTR amyloidosis&#xD;
&#xD;
          2. Any past history of or present abuse of alcohol, diabetes, B12 or folate deficiencies,&#xD;
             autoimmune diseases, hereditary disorders other than transthyretin (eg,&#xD;
             Charcot-Marie-Tooth), uncontrolled hypothyroidism, or other etiologies for the&#xD;
             peripheral neuropathy&#xD;
&#xD;
          3. Received prior liver transplant&#xD;
&#xD;
          4. Planned liver transplant during the study&#xD;
&#xD;
          5. Modified body mass index (mBMI) ≤600 kg/m2 × g/L&#xD;
&#xD;
          6. New York Heart Association (NYHA) Functional Class III-IV (Appendix 2)&#xD;
&#xD;
          7. LVEF ≤45%&#xD;
&#xD;
          8. Uncontrolled symptomatic orthostatic hypotension&#xD;
&#xD;
          9. Myocardial infarction, unstable or uncontrolled angina, severe uncontrolled&#xD;
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6&#xD;
             months prior to the first dose of study drug&#xD;
&#xD;
         10. Any history of clinically significant sinus pauses on ECG&#xD;
&#xD;
         11. Sinus pauses &gt;3 seconds in the day or sinus pauses &gt;5 seconds at night during the&#xD;
             48-hour pre-dose cardiac monitoring (ie, prior to first dose of study drug)&#xD;
&#xD;
         12. Arrhythmia requiring treatment diagnosed during the 48-hour pre-dose cardiac&#xD;
             monitoring (ie, prior to first dose of study drug). Note: subject could be&#xD;
             reconsidered for entry into the study if appropriate treatment is obtained&#xD;
&#xD;
         13. Hospitalized for heart failure within the 12 weeks prior to the first dose of study&#xD;
             drug&#xD;
&#xD;
         14. Uncontrolled infection, or active malignancy with the exception of the following:&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or&#xD;
                  in situ cervical cancer&#xD;
&#xD;
               -  Low risk prostate cancer with Gleason score &lt;7 and prostate specific antigen &lt;10&#xD;
                  mg/mL&#xD;
&#xD;
               -  Any other cancer from which the subject has been disease-free for ≥2 years&#xD;
&#xD;
         15. Clinically significant pleural effusion per Investigator (e.g., presence of pleural&#xD;
             effusion ≥30% in either hemithorax)&#xD;
&#xD;
         16. History of Grade ≥3 hypersensitivity-associated AEs or hypersensitivities to other&#xD;
             monoclonal antibodies or the excipients found in the PRX004 formulation&#xD;
&#xD;
         17. Known HIV infection or known hepatitis B or C virus carrier&#xD;
&#xD;
         18. Women who are pregnant or breastfeeding&#xD;
&#xD;
         19. Treatment with an investigational agent within 30 days or 5 half-lives (whichever is&#xD;
             longer) prior to Month 1-Day 1&#xD;
&#xD;
         20. Any condition which could interfere with, or the treatment for which might interfere&#xD;
             with, the conduct of the study or which would, in the opinion of the Medical Monitor&#xD;
             or Investigator unacceptably increase the subject's risk by participating in the study&#xD;
&#xD;
         21. Treatment with patisiran or inotersen within 90 days or 5 halflives (whichever is&#xD;
             longer) prior to Month 1-Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

